{"id":469507,"date":"2025-06-05T00:00:00","date_gmt":"2025-06-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0010-2025-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-unmet-need-recurrent-or-metastatic-non\/"},"modified":"2026-03-31T10:26:04","modified_gmt":"2026-03-31T10:26:04","slug":"unneon0010-2025-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-unmet-need-recurrent-or-metastatic-non","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0010-2025-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-unmet-need-recurrent-or-metastatic-non\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck – Unmet Need – Unmet Need – Recurrent or Metastatic Non-Nasopharyngeal Squamous Cell Carcinoma of Head and Neck (US\/EU)"},"content":{"rendered":"
\n

Recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck is an aggressive malignancy associated with a high recurrence rate. The approval of immune checkpoint inhibitors, such as Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb), over the past decade has significantly altered the treatment paradigm. In the first-line setting, Keytruda is the current SOC, while Erbitux (Eli Lilly [United States] \/ Merck KGaA [EU5]) is prescribed for PD-L1-negative or immunotherapy-ineligible patients. In the second-line setting, Keytruda is approved as monotherapy, regardless of PD-1 expression. However, there is a strong need for effective therapies that prolong overall survival in this patient population. In addition, there is an unmet need for patients with non-nasopharyngeal SCCHN who have progressed after treatment with immune checkpoint inhibitors because there are no established therapies for this patient population.<\/p>\n<\/div>\n

\n

Questions answered <\/strong><\/p>\n<\/div>\n

\n
    \n
  • What are the treatment drivers and goals in medical oncologists\u2019 prescribing decisions for recurrent or metastatic non-nasopharyngeal SCCHN?<\/li>\n
  • How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for this patient population?<\/li>\n
  • What are the prevailing areas of unmet need and hidden opportunities that drug developers could leverage in the treatment?<\/li>\n
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical target product profile?<\/li>\n<\/ul>\n<\/div>\n
    \n

    Product description <\/strong><\/p>\n<\/div>\n

    \n

    Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<\/div>\n

    \n
      \n
    • Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n
    • Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n
    • Analyze market scenarios for different target product profiles using the TPP Simulator.<\/li>\n<\/ul>\n
      \n

      Key feature <\/strong><\/p>\n<\/div>\n

      \n

      Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n

      \n

      Markets covered:<\/strong>\u00a0United States, France, Germany, United Kingdom<\/p>\n<\/div>\n

      <\/div>\n
      \n

      Primary research:<\/strong>\u00a0Survey of 65 U.S. and 35 European medical oncologists<\/p>\n<\/div>\n

      <\/div>\n
      \n

      Key drugs covered:<\/strong>\u00a0Erbitux, Keytruda, Opdivo<\/p>\n<\/div>\n

      <\/div>\n
      \n

      Key analyses <\/strong><\/p>\n<\/div>\n

      \n

      Importance of clinical and nonclinical product attributes to physicians<\/p>\n<\/div>\n

      \n

      Assessment of current drug performance against treatment drivers and goals<\/p>\n<\/div>\n

      \n

      Physician perceptions of unmet needs in the indication and related indications<\/p>\n<\/div>\n

      \n

      Remaining drug development opportunities<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"template":"","class_list":["post-469507","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-solid-tumors","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469507\/revisions"}],"predecessor-version":[{"id":575781,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469507\/revisions\/575781"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=469507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}